Suggested remit: To appraise the clinical and cost effectiveness of futibatinib within its marketing authorisation for treating cholangiocarcinoma.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6302

Provisional Schedule

Committee meeting 02 July 2024
Expected publication 11 September 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Taiho Pharma Europe (futibatinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups AMMF – The Cholangiocarcinoma Charity
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Incyte Biosciences (pemigatinib) (confidentiality agreement returned, participating)
  Hospira UK (fluorouracil, oxaliplatin) (confidentiality agreement not returned, not participating)
  Medac (folinic acid, fluorouracil, oxaliplatin) (confidentiality agreement not returned, not participating)
  Ranbaxy, a Sun Pharmaceutical company (oxaliplatin) (confidentiality agreement not returned, not participating)
  Seacross Pharmaceuticals (oxaliplatin) (confidentiality agreement not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
20 November 2023 Invitation to participate
04 October 2023 - 01 November 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6302
03 August 2023 In progress. DHSC referral received
06 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual